Archives: Press Releases

PALO ALTO, Calif., March 28, 2023 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022. “We are running a comprehensive development program for tarcocimab tedromer with topline data from four … Continued

PALO ALTO, Calif., May 10, 2022 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2022. “We learned in February that our Phase 2b/3 study in wet AMD did not meet its primary endpoint,” said Victor … Continued

PALO ALTO, Calif., April 29, 2022 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that presentations of clinical study data on its investigational therapy KSI-301 will be made at two upcoming vision research conferences: the Association for Research in Vision and Ophthalmology (ARVO) … Continued

PALO ALTO, Calif., March 1, 2022 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2021. “Although our Phase 2b/3 pivotal study in wet AMD did not meet its primary efficacy endpoint, … Continued

– The study did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks– Nearly 60% of KSI-301 patients achieved every 5-month dosing at year 1 with visual acuity gains and anatomic improvements comparable to the overall aflibercept group– KSI-301 was safe and well tolerated, with no … Continued

– Over 900 patients with diabetic macular edema enrolled worldwide PALO ALTO, Calif., Feb. 3, 2022 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its GLEAM and GLIMMER Phase 3 clinical trials of KSI-301, Kodiak’s … Continued

PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 11:15 a.m. Pacific Time (2:15 p.m. Eastern Time). A live webcast of the … Continued

− Over 550 patients with macular edema secondary to Retinal Vein Occlusion enrolled worldwide PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its BEACON Phase 3 clinical trial of KSI-301, … Continued

PALO ALTO, Calif., Nov. 9, 2021 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2021. “We are pleased with the operational progress across our pivotal clinical program,” said Victor Perlroth, MD, Chief … Continued

Pay for Performance: Program Aligns Incentives to Significant Value Creation through Share Price Milestones of $200 to $800 per Share PALO ALTO, Calif., Sept. 1, 2021  /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced new seven-year performance stock option awards under a … Continued